- Realm Therapeutics said it had been awarded two new US patents related to its proprietary immunomodulatory technology.

The United States Patent and Trademark Office issued notices of allowance for the patents, with application numbers 15/170,046 and 14/670,641.

'These patent allowances expand the breadth of our intellectual property estate and further validate the proprietary nature of our immunomodulatory technology,' Realm chief executive Alex Martin said.

'As we look forward to the results of our Phase 2 study for PR013 in allergic conjunctivitis later in the first quarter, as well as the results of our Phase 2 trial for PR022 in atopic dermatitis in the third quarter, we are gratified to have even stronger patent protection for our dermatology and ophthalmology programs.'

At 2:32pm: [LON:RLM] Realm Therapeutics Plc share price was +0.5p at 47.5p

Story provided by